Drugs and Diagnostics for Hematological Disorders: Global Markets - Product Image

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • ID: 3885109
  • Report
  • Region: Global
  • 504 Pages
  • BCC Research
20%OFF
until Jun 30th 2018
1 of 5
The Global Market for Hematology Drugs and Diagnostics is Expected to Grow from Nearly $86.5 Billion in 2015 to $124.3 Billion in 2020 at a CAGR rate of 7.5%

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca
  • Chugai Pharmaceutical
  • Erytech Pharma Sa
  • Horiba Ltd.
  • Pharmacyclics
  • MORE
The global market for hematology drugs and diagnostics is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a compound annual growth rate of 7.5% from 2015-2020.

This report provides:

- An overview of the global market for drugs and diagnostics for hematological disorders.
- Analyses of global market trends, with data from2015, and projections of CAGRs through 2020.
- A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.
- A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.
- Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Delineation of drugs approved by the FDA for hematological disorders.
- Profiles of key companies in the industry.

The scope of this study covers instruments, reagents, testing, screening technology and the therapeutics markets for hematological disorders, including hemophilia and blood cancers. The report also discusses the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends, and clinical and new developments.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca
  • Chugai Pharmaceutical
  • Erytech Pharma Sa
  • Horiba Ltd.
  • Pharmacyclics
  • MORE
1: Introduction
- Study Goals And Objectives
- Reasons For Doing This Study
- Intended Audience
- Scope Of The Study
- Methodology
- Information Sources

2: Summary
- - Table Summary : Global Market For Hematology Drugs And Diagnostics, By Segment, Through 2020
- - Figure Summary : Global Market For Hematology Drugs And Diagnostics, By Segment, 2012-2020

3: Hematalogical Disorders
- Blood
- Blood Disorders/Diseases
- - Table 1 : Key Blood Disorders
- - Table 2 : Malignant Blood Disorders
- - Table 3 : Nonmalignant Blood Disorders

4: Hematological Cancers
- Classic Classification
- - Table 35 : Hematological Cancers (Blood Cancers)

5: Leukemia
- Lymphocytic Leukemias
- Myelogenous Leukemias
- Conclusions

6: Lymphoma
- Overview
- Non-Hodgkin Lymphoma
- Lymphoma Treatment

7: Multiple Myeloma
- Overview
- Conclusions

8: Myelodysplastic Syndromes
- Classes Of Mds
- Diagnosis And Tests
- Prognosis And Treatment Options
- Drug Profiles
- Conclusions
- - Table 84 : Characteristics Of Mds
- - Table 85 : Causes Of Mds
- - Table 86 : Mds Or Aml: Three Categories

9: Myeloproliferative Disorders
- Types Of Chronic Myeloproliferative Disorders
- Stages Of Chronic Myeloproliferative Disorders
- Diagnosis
- Treatment
- Polycythemia Vera
- Chronic Idiopathic Myelofibrosis
- Essential Thrombocythemia
- Chronic Neutrophilic Leukemia
- Chronic Eosinophilic Leukemia
- Summary

10: Epidemiology Of Hematological Cancers
- India
- Kenya
- Worldwide Incidence Of Blood Cancers
- Leukemia
- Lymphoma
- Myeloma
- Myelodysplastic Syndromes
- Blood Diseases And Incidence
- Bleeding Disorders
- - Table 115 : Cancer Key Facts
- - Table 116 : Increase In Cancer Burden: Factors

11: Hematology Instruments And Reagents: A Global Market Perspective
- Hematological Malignancies
- Market Dynamics: Hematology Instruments And Reagents
- Hematology Test Products And Market
- Conclusions

12: Global Market For Treatments For Hematological Disorders
- Therapeutic Drug Market
- Conclusions

13: Hematological Cancer Therapies Market
- Overview
- Hematological Cancers Drug Market
- Classification Of Hematologic Malignancies
- Global Cytotoxic Therapies Market
- Leukemia Market And Challenges
- Chronic Myelogenous Leukemia Market
- Acute Lymphocytic Leukemia Market
- Acute Myeloid Leukemia (Aml) Market
- Chronic Lymphocytic Leukemia Market
- Lymphoma Drug Market
- Multiple Myeloma Treatment Market
- Myelodysplastic Syndrome Market
- Myeloproliferative Disorders
- Market For Essential Thrombocytosis (Et)
- Myelofibrosis Market
- Polycythemia Vera (Pv) Therapeutics Market

14: Patent Landscape And Current Developments
- Hematological Cancer Drug Patent Expiries
- New Approvals
- - Table 291 : Major Blood Disorder Drug Patent Expiries, 2009-2015
- - Table 292 : Key Blood Disorder Drugs: Patent Expiry
- - Table 293 : Drugs Losing Patent Protection By 2015, Global Sales 2010

15: Selected Company Profiles
- Abbott Laboratories
- Abon Pharmaceuticals
- Ambit Biosciences
- Amgen
- Amphastar Pharmaceuticals
- Ariad Pharmaceuticals
- Astellas Pharma Us
- Astex Pharmaceuticals
- Astrazeneca
- Baxalta Inc.
- Baxter Healthcare Corp.
- Bayer Healthcare Pharmaceuticals
- Biogen Idec
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb
- Celgene Corp.
- Chugai Pharmaceutical
- C.R. Bard
- CZ Biomed Corp.
- Daiichi Sankyo Co. Ltd.
- Deciphera Pharmaceuticals
- Diagnocure
- Eisai Inc.
- ELI Lilly And Co.
- Enzon Pharmaceuticals
- Erytech Pharma Sa
- Exelixis
- GE Healthcare
- Genentech Inc.
- Genmab Inc.
- Gilead Sciences
- Glaxosmithkline
- Hologic
- Horiba Ltd.
- Johnson & Johnson
- The Medicines Co.
- Medkoo Biosciences
- Momenta Pharmaceuticals
- Noxxon Pharma Ag
- Portola Pharmaceuticals Inc.
- Opko Health
- Otsuka Pharmaceutical
- Pfizer
- Pharmacyclics
- Roche Diagnostics
- Sandoz International Gmbh
- Sanofi
- Siemens AG
- Spectrum Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Watson Pharmaceuticals Inc.
- YM Biosciences Inc.

16: Bibliography

List Of Tables

Summary Table : Global Market For Hematology Drugs And Diagnostics, By Segment, Through 2020
Table 1 : Key Blood Disorders
Table 2 : Malignant Blood Disorders
Table 3 : Nonmalignant Blood Disorders
Table 4 : Type Of Blood Cells And Functions
Table 5 : Components Of Blood
Table 6 : Three Major Types Of Anemia
Table 7 : Causes Of Anemia
Table 8 : Symptoms Of Anemia
Table 9 : Anemia: Types, Causes And Treatment
Table 10 : Drugs That Can Cause Cobalamin Deficiency By Class
Table 11 : Drugs That Can Cause Folate Deficiency
Table 12 : Sickle Cell Anemia: Key Facts
Table 13 : Lab Tests For Anemia
Table 14 : Hemostasis: Three Major Steps
Table 15 : Drugs That Affect The Activity Of Platelets
Table 16 : Anticoagulants That Act On Thrombin
Table 17 : Bleeding Disorders
Table 18 : Symptoms Of Bleeding Disorders
Table 19 : Signs And Tests For Bleeding Disorders
Table 20 : Key Characteristics Of Hemophilia
Table 21 : Fviii Inhibitors
Table 22 : Medications For Treating Hemophilia
Table 23 : Factor Viii Products
Table 24 : Antifibrinolytics By Drug
Table 25 : Antihemophilic Agents By Class
Table 26 : Formation Of Thrombus
Table 27 : Causes Of Neutropenia
Table 28 : White Blood Cell Disorders
Table 29 : Causes Of Secondary Thrombocytosis
Table 30 : Diagnostic Tests For Thrombocythemia
Table 31 : Medicines For Thrombocythemia
Table 32 : Causes Of Thrombocytopenia
Table 33 : Signs Of External Bleeding
Table 34 : Common Drugs To Treat Eosinophilia
Table 35 : Hematological Cancers (Blood Cancers)
Table 36 : Relative Occurrence Of Hematological Malignancies In The U.S., 2016
Table 37 : Types Of Hematological Cancers
Table 38 : Fda Approvals Of Drugs For Hematological Disorders/Diseases, 2014-2016
Table 39 : Fda Approvals Of Drugs For Hematological Disorders/Diseases, 2012
Table 40 : Fda Approvals Of Drugs For Hematological Disorders/Diseases, 2011
Table 41 : Fda Approvals Of Drugs For Hematological Disorders/Diseases, 1996-2010
Table 42 : Types Of Leukemia
Table 43 : Types Of Leukemia And Key Features
Table 44 : Diagnostic Exams For Leukemia
Table 45 : Additional Tests
Table 46 : Pcr Tests
Table 47 : Non-Laboratory Tests
Table 48 : Common Treatments Used To Fight Leukemia
Table 49 : Newer Classes Of Drugs
Table 50 : Acute Lymphoblastic Leukemia Treatment
Table 51 : Drugs Approved For Acute Lymphoblastic Leukemia
Table 52 : Drugs Approved For Chronic Lymphocytic Leukemia
Table 53 : Drugs Approved For Acute Myeloid Leukemia
Table 54 : Drugs Approved For Chronic Myelogenous Leukemia
Table 55 : T-Cell Prolymphocytic Leukemia: Treatment Plan
Table 56 : Factors Affecting Leukemia Staging And Prognosis
Table 57 : Chemotherapy Drugs For Cml
Table 58 : Chemotherapy Drugs For Cll
Table 59 : Targeted Therapy Drugs
Table 60 : Advantages Of Radioimmunotherapy
Table 61 : Common Radiation Treatments: Leukemia
Table 62 : Pain Medications
Table 63 : Emerging Therapies For Leukemia
Table 64 : Causes Of Lymphoma
Table 65 : Lymphoma Types
Table 66 : Staging For Hl And Nhl Tumors
Table 67 : Mature B-Cell Neoplasms
Table 68 : Mature T-Cell And Natural Killer Cell Neoplasms
Table 69 : Hodgkin Lymphoma
Table 70 : Immunodeficiency-Associated Lymphoproliferative Disorders
Table 71 : Symptoms Of Non-Hodgkin Lymphoma
Table 72 : Five-Year Relative Survival By Stage At Diagnosis: Non Hodgkin Lymphoma, 2006-2012
Table 73 : Imaging Tests For Lymphoma
Table 74 : The International Prognostic Index For Hl
Table 75 : The International Prognostic Index For Nhl
Table 76 : Promising Therapies For Treating Lymphoma
Table 77 : Prognostic Indicators For Myeloma
Table 78 : Other Bone Marrow Tests
Table 79 : Myeloma: Staging Criteria
Table 80 : Myeloma's Response To Treatment
Table 81 : Supportive Care For Myeloma
Table 82 : Drugs For Multiple Myeloma
Table 83 : New And Emerging Therapies For Myeloma
Table 84 : Characteristics Of Mds
Table 85 : Causes Of Mds
Table 86 : Mds Or Aml: Three Categories
Table 87 : Myelodysplastic Syndromes: Key Facts
Table 88 : Fab Classification Of Mds
Table 89 : The 2008 Who Classification Of Mds
Table 90 : International Prognostic Scoring System Risk Groups And Prognos
Table 91 : Changes In Cells Due To Mds
Table 92 : Chronic Myeloproliferative Disorders
Table 93 : Classification Of Myeloid Neoplasms According To The 2008 Who Classification Scheme
Table 94 : Myeloproliferative Neoplasms: Key Facts
Table 95 : Diagnostic Tests
Table 96 : Symptoms Of Polycythemia Vera
Table 97 : Blood Tests For Polycythemia Vera
Table 98 : Treatment For Polycythemia Vera
Table 99 : Causative Factors For Myelofibrosis
Table 100 : Potential Complications From Myelofibrosis
Table 101 : Who Diagnostic Criteria For Pmf
Table 102 : Risk Factors
Table 103 : Idiopathic Myelofibrosis And Symptoms
Table 104 : Prognosis Factors
Table 105 : Treatment Of Chronic Idiopathic Myelofibrosis
Table 106 : Somatic Mutations
Table 107 : Causes Of Thrombocytosis
Table 108 : Symptoms Of Essential Thrombocytosis
Table 109 : Essential Thrombocythemia: Diagnostic Criteria
Table 110 : Treatment Of Et
Table 111 : Treatment Of Chronic Neutrophilic Leukemia
Table 112 : Symptoms Of Chronic Eosinophilic Leukemia
Table 113 : Treatment Of Chronic Eosinophilic Leukemia
Table 114 : Current Drugs
Table 115 : Cancer Key Facts
Table 116 : Increase In Cancer Burden: Factors
Table 117 : Global Incidence Of Blood Cancers, 2012
Table 118 : Global Incidence Of Blood Cancers, 2012
Table 119 : Global Incidence Of Blood Cancers In Men, 2012
Table 120 : Global Incidence Of Blood Cancers In Women, 2012
Table 121 : Top 10 Countries' Cancer Incidence Rates
Table 122 : Estimated Incidence Of Blood Cancers In The U.S., 2011 Vs. 2016
Table 123 : Estimated New Cases Of Leukemia, Lymphoma And Myeloma In The U.S., 2016
Table 124 : Estimated Leukemia And Lymphoma Incidence And Deaths In The U.S., 2016
Table 125 : Global Incidence Of Leukemia, 2012
Table 126 : U.S. Leukemia Incidence Statistics, 2012
Table 127 : Estimated New Cases Of Leukemia And Deaths In The U.S., 2010-2016
Table 128 : Estimated New Cases Of Leukemia In Adults And Children In The U.S., 2016
Table 129 : Estimated Prevalence Of Different Types Of Leukemia In The U.S., 2008
Table 130 : Prevalence Of Leukemia In The U.S., 2016
Table 131 : Types Of Leukemia In Adults In The U.S. And Age Group
Table 132 : Estimated Leukemia Incidence And Deaths In The U.S. By Type, 2012
Table 133 : Age-Adjusted Incidence Rates Of Leukemia In The U.S. By Race, Seer 18, 2009-2013
Table 134 : Five-Year Relative Survival Rates In The U.S. For Leukemia, 2005-2011
Table 135 : Estimated Deaths From Leukemia In The U.S., 2016
Table 136 : New Cases Of Leukemia In The U.K., 2013
Table 137 : Global Estimates Of Leukemia Deaths/Mortality Rates, 2012
Table 138 : Global Estimated Incidence Rates Of Non-Hodgkin Lymphoma For All Ages And Both Sexes, 2012
Table 139 : Global Estimated Non-Hodgkin Lymphoma Mortality Rates By All Ages And Both Sexes, 2012
Table 140 : Global Estimated Incidence Of Hodgkin Lymphoma For All Ages And Both Sexes, 2012
Table 141 : Estimated Incidence Of Non-Hodgkin Lymphoma In Eu-27 Countries By Gender, 2008
Table 142 : Estimated Non-Hodgkin Lymphoma Mortality Rates In Eu-27 Countries By Gender, 2008
Table 143 : Estimated Hodgkin Lymphoma Incidence And Mortality Rates In Eu-27 Countries, 2012
Table 144 : Estimated Lymphoma Incidence And Deaths In The U.S., 2016
Table 145 : Estimated Lymphoma Incidence And Deaths In The U.S., 2011-2012
Table 146 : Estimated New Cases Of Lymphoma In The U.S. By Type, 2011-2016
Table 147 : Estimated New Cases Of Lymphoma In The U.S. By Type And Gender, 2012
Table 148 : Estimated Deaths From Lymphoma In The U.S. By Type And Gender, 2011
Table 149 : U.S. Age-Specific Nhl Incidence Rates By Gender
Table 150 : U.S. Lymphoma Incidence Rates By Race, 2005-2009
Table 151 : U.S. Lymphoma Mortality Rates By Race, 2005-2009
Table 152 : Stage Distribution And Five-Year Relative Survival Of All Races, Both Sexes By Stage At Diagnosis, 2002-2008
Table 153 : New Cases Of Non-Hodgkin Lymphoma In The U.K., 2013
Table 154 : Non-Hodgkin Lymphoma Deaths In The U.K. By Sex, 2012
Table 155 : Estimated Number Of New Cases Of Hodgkin Lymphoma In The U.K., 2013
Table 156 : Estimated Number Of Deaths From Hodgkin's Lymphoma In The U.K., 2012
Table 157 : Estimated Global Incidence Of Myeloma, 2008
Table 158 : Estimated Global Myeloma Mortality Rates By Region, 2008
Table 159 : Estimated Incidence Of Myeloma In Eu-27 Countries, 2012
Table 160 : Deaths From Myeloma In Eu-27 Countries, 2012
Table 161 : Estimated Myeloma Incidence And Deaths In The U.S., 2011-2016
Table 162 : Estimated Incidence Of Myeloma By Gender In The U.S., 2011-2016
Table 163 : Age-Adjusted Incidence Rates Of Myeloma In The U.S. By Race, Seer 18 2009-2013
Table 164 : Age-Adjusted Death Rates From Myeloma In The U.S. By Race, Seer 18 2009-2013
Table 165 : Distribution And Five-Year Relative Survival For All Ages And Both Sexes In The U.S. By Stage At Diagnosis, 2002-2008
Table 166 : New Cases Of Myeloma In The U.K., 2013
Table 167 : Myeloma Deaths In The U.K., 2012
Table 168 : Estimated New Cases Of Mds In The U.S., 2012
Table 169 : Key Factors Driving The Growth Of The Hematological Disorders Market
Table 170 : Global Hematology Instruments And Reagents Market, Through 2020
Table 171 : Key Hematology Products
Table 172 : Global Major Companies In The Hematology Market
Table 173 : Key Players In Flow Cytometry
Table 174 : Global Flow Cytometry Instruments And Reagents Market, Through 2020
Table 175 : Major Flow Cytometry Applications
Table 176 : Cell Analyzers
Table 177 : Hematology Tests
Table 178 : Complete Blood Count: Components Measured
Table 179 : Tests Included In A Chemistry Screen
Table 180 : Chemistry Screen
Table 181 : Urine Tests And Applications
Table 182 : Global Ivd Products Market, Through 2020
Table 183 : U.S. Ivd Market, Through 2020
Table 184 : Global Market For Immunoassay Systems, Through 2020
Table 185 : Global Market For Enzyme Immunoassay Systems, Through 2020
Table 186 : Key Players In The Immunoassays Market
Table 187 : Global Molecular Diagnostics Market, Through 2020
Table 188 : Major Players In Molecular Diagnostics Market
Table 189 : Global Point-Of-Care Testing Market, Through 2020
Table 190 : Poc Testing Kits
Table 191 : Global Market For Poc Tests, Through 2020
Table 192 : Global Point-Of-Care Immunoassay Market, Through 2020
Table 193 : Types Of Cardiac Markers
Table 194 : Key Market Players In The Blood Screening Market
Table 195 : Global Market For Treatments For Hematological Disorders, By Type, Through 2020
Table 196 : Global Market Shares Of Treatments For Hematological Disorders By Type, 2015 And 2020
Table 197 : Patent Expiries Of Major Blockbusters Drugs
Table 198 : Global Key Players Of Hematological Disorders Market By Products And Market Share, 2015
Table 199 : Market Drivers Of Hematological Disorders
Table 200 : Market Restraints Of Hematological Disorders
Table 201 : Global Anemia Treatment Market, Through 2020
Table 202 : Types Of Anemia
Table 203 : Common Anemia Treatments
Table 204 : Erythropoietin Stimulating Agents
Table 205 : Key Anemia Drugs Sales, 2012 And 2015
Table 206 : Global Neorecormon Market, 2010-2015*
Table 207 : Global Neorecormon Market, 2009
Table 208 : Biosimilars Of Epoetin Alfa And Darbepoetin Alfa
Table 209 : Akebia Therapeutics: Anemia Drug In Development-Akb-6548
Table 210 : Global Antithrombotic Drug Market, By Type, Through 2020
Table 211 : Leading Drugs In The Antithrombotic Agents Market
Table 212 : Global Anticoagulant Drug Market, Through 2020
Table 213 : Global Antiplatelet Drug Market, Through 2020
Table 214 : Some Common Antiplatelet And Anticoagulant
Table 215 : Global Antiplatelet Drugs Market, Through 2020
Table 216 : U.S. Sales Of Plavix, 2012
Table 217 : Global Antithrombotic Agents Market, Through 2020
Table 218 : Xarelto: Approvals In Venous Arterial Thromboembolic Indications
Table 219 : Global Activase Market, Through 2020
Table 220 : Key Platelet Aggregation Inhibitor Drug Market, 2012 And 2015
Table 221 : Platelet Aggregation Inhibitors: Pipeline Drugs
Table 222 : Key Players In The Global Heparin Market
Table 223 : Thrombosis Market: Pipeline Drugs
Table 224 : Platelet Inhibitor: Pipeline Drugs
Table 225 : Global Neutropenia Drug Market, Through 2020
Table 226 : Company Market Shares Of Key Neutropenia Drugs, 2015
Table 227 : Growth Factors For Treating Neutropenia
Table 228 : Global Neulasta/Neupogen Market, 2012 And 2015
Table 229 : Global Sargramostim Market, 2010
Table 230 : Companies With Short-Acting Filgrastims In Phase Iii Clinical Development In Europe
Table 231 : Filgrastim Products
Table 232 : Global Hemophilia Therapeutics Market, Through 2020
Table 233 : Global Key Hemophilia Players
Table 234 : Key Hemophilia Drugs
Table 235 : Global Market For Recombinant Coagulation Factors For Hemophilia, By Type, 2010
Table 236 : Other Coagulation Products
Table 237 : Gene Therapy Programs In Hemophilia
Table 238 : Fda Approved Drugs For Hematology, Aug. 2013-March 2016
Table 239 : Approvals By Health Canada, March 2014-Jan. 2016
Table 240 : Cancer In The United States
Table 241 : Cytotoxic Therapies Market Indications
Table 242 : List Of Medications
Table 243 : Global Cytotherapeutics Market, 2010 And 2017
Table 244 : U.S. Cytotherapeutics Market, 2012 And 2017
Table 245 : European Cytotherapeutics Market, 2012 And 2017
Table 246 : Japanese Cytotherapeutics Market, 2012 And 2017
Table 247 : Major Leukemia Players
Table 248 : Recent Leukemia Incidence Percentage By Category
Table 249 : Global Leukemia Market, By Type, Through 2020
Table 250 : Leukemia Market Share Forecast, By Country, 2011
Table 251 : U.S. Leukemia Market, Through 2020
Table 252 : European Leukemia Market, Through 2020
Table 253 : Japan's Leukemia Market, Through 2020
Table 254 : Global Leukemia Market By Region, Through 2020
Table 255 : Global Chronic Myelogenous Leukemia Market, Through 2020
Table 256 : Drug Classes' For Leukemia Drug Development
Table 257 : Key Chronic Myelogenous Leukemia Market, By Drug, 2010-2015
Table 258 : Key Cml Medicines And Cost
Table 259 : Gleevac Fda Approvals, 2002-2012
Table 260 : Recent Pipeline Drugs For Leukemia
Table 261 : Global Acute Lymphocytic Leukemia Therapeutics Market, Through 2020
Table 262 : Major Acute Lymphocytic Leukemia Players In The Market
Table 263 : Drugs For Acute Lymphocytic Leukemia (All) Treatment
Table 264 : Approved Drugs For All
Table 265 : Global Acute Myeloid Leukemia Market, Through 2020
Table 266 : Key Companies In The Aml Market
Table 267 : Global Chronic Lymphocytic Leukemia Market, Through 2020
Table 268 : Global Arzerra Market, 2010-2015
Table 269 : Global Treanda Market, 2014-2017
Table 270 : Nox-A12: How Does It Work?
Table 271 : Gilead: Hematology And Oncology Pipeline
Table 272 : Generic Drugs Used In Combination To Treat Hodgkin Lymphoma
Table 273 : Drugs Used In Combination To Treat Non-Hodgkin Lymphoma
Table 274 : Global Non-Hodgkin Lymphoma Drug Market, Through 2020
Table 275 : Global Rituximab Market, 2010-2015
Table 276 : Rituxan: Biosimilars In Development
Table 277 : Global Revlimid Market, 2011-2015
Table 278 : Global Hodgkin Lymphoma Treatment Market, Through 2020
Table 279 : Global Multiple Myeloma Treatment Market, Through 2020
Table 280 : Drugs For The Myeloma Market
Table 281 : Pipeline Drugs For Myeloma In Development
Table 282 : Treanda Clinical Trials In Relapsed And/Or Refractory Myeloma
Table 283 : Global Myelodysplastic Syndrome Market, Through 2020
Table 284 : Approved Drugs For The Treatment Of Mds
Table 285 : Drugs In Clinical Development
Table 286 : Global Myeloproliferative Disorders Market, Through 2020
Table 287 : Jak2 Inhibitors In Development
Table 288 : Global Jakafi/Ruxolitinib Market, Through 2020
Table 289 : Global Myelofibrosis Market, Through 2020
Table 290 : Global Polycythemia Vera Market, Through 2020
Table 291 : Major Blood Disorder Drug Patent Expiries, 2009-2015
Table 292 : Key Blood Disorder Drugs: Patent Expiry
Table 293 : Drugs Losing Patent Protection By 2015, Global Sales 2010
Table 294 : Biologic Drug Patent Expiries
Table 295 : New Drug Approvals For Blood Disorders, 2012
Table 296 : New Drug Approvals For Hematological Cancers, 2012

List Of Figures

Summary Figure : Global Market For Hematology Drugs And Diagnostics, By Segment, 2012-2020
Figure 1 : Estimated Incidence Of Blood Cancers, In The U.S., 2011 Vs. 2016
Figure 2 : Estimated New Cases Of Leukemia, Lymphoma And Myeloma In The U.S., 2016
Figure 3 : Estimated Leukemia And Lymphoma Incidence And Deaths In The U.S., 2016
Figure 4 : Estimated New Cases Of Leukemia And Deaths In The U.S., 2010-2016
Figure 5 : Estimated Prevalence Of Different Types Of Leukemia In The U.S., 2008
Figure 6 : Prevalence Of Leukemia In The U.S., 2016
Figure 7 : Estimated Leukemia Incidence And Deaths In The U.S. By Type, 2012
Figure 8 : Estimated Deaths From Leukemia In The U.S., 2016
Figure 9 : Estimated Incidence Of Non-Hodgkin Lymphoma In Eu-27 Countries By Gender, 2008
Figure 10 : Estimated Non-Hodgkin Lymphoma Mortality Rates In Eu-27 Countries By Gender, 2008
Figure 11 : Estimated Hodgkin Lymphoma Incidence And Mortality Rates In Eu-27 Countries, 2012
Figure 12 : Estimated Lymphoma Incidence And Deaths In The U.S., 2016
Figure 13 : Estimated Lymphoma Incidence And Deaths In The U.S., 2011-2012
Figure 14 : Estimated New Cases Of Lymphoma In The U.S. By Type, 2011-2016
Figure 15 : Estimated New Cases Of Lymphoma In The U.S. By Type And Gender, 2012
Figure 16 : Estimated Deaths From Lymphoma In The U.S. By Type And Gender, 2011
Figure 17 : Estimated Number Of Deaths From Hodgkin’S Lymphoma In The U.K., 2012
Figure 18 : Estimated Global Incidence Of Myeloma, 2008
Figure 19 : Estimated Global Myeloma Mortality Rates By Region, 2008
Figure 20 : Estimated Myeloma Incidence And Deaths In The U.S., 2011-2016
Figure 21 : Estimated Incidence Of Myeloma By Gender In The U.S., 2011-2016
Figure 22 : Global Hematology Instruments And Reagents Market, 2012-2020
Figure 23 : Global Flow Cytometry Instruments And Reagents Market, 2012-2020
Figure 24 : Global Ivd Products Market, 2012-2020
Figure 25 : U.S. Ivd Market, 2012-2020
Figure 26 : Global Market For Immunoassay Systems, 2012-2020
Figure 27 : Global Market For Enzyme Immunoassay Systems, 2015-2020
Figure 28 : Global Molecular Diagnostics Market, 2015-2020
Figure 29 : Global Point-Of-Care Testing Market, 2015-2020
Figure 30 : Global Market For Poc Tests, 2015-2020
Figure 31 : Global Point-Of-Care Immunoassay Market, 2015-2020
Figure 32 : Global Market For Treatments For Hematological Disorders, By Type, 2012-2020
Figure 33 : Global Anemia Treatment Market, 2012-2020
Figure 34 : Key Anemia Drugs Sales, 2012 And 2015
Figure 35 : Global Neorecormon Market, 2010-2015*
Figure 36 : Global Antithrombotic Drug Market, By Type, 2012-2020
Figure 37 : Global Anticoagulant Drug Market, 2012-2020
Figure 38 : Global Antiplatelet Drug Market, 2012-2020
Figure 39 : Global Neutropenia Drug Market, 2012-2020
Figure 40 : Global Hemophilia Therapeutics Market, 2012-2020
Figure 41 : Global Market For Recombinant Coagulation Factors For Hemophilia, By Type, 2010
Figure 42 : Global Cytotherapeutics Market, 2010 And 2017
Figure 43 : U.S. Cytotherapeutics Market, 2012 And 2017
Figure 44 : European Cytotherapeutics Market, 2012 And 2017
Figure 45 : Japanese Cytotherapeutics Market, 2012 And 2017
Figure 46 : Global Leukemia Market, By Type, 2012-2020
Figure 47 : U.S. Leukemia Market, 2012-2020
Figure 48 : European Leukemia Market, 2012-2020
Figure 49 : Japan's Leukemia Market, 2012-2020
Figure 50 : Global Leukemia Market By Region, 2012-2020
Figure 51 : Global Chronic Myelogenous Leukemia Market, 2012-2020
Figure 52 : Key Chronic Myelogenous Leukemia Market, By Drug, 2010-2015
Figure 53 : Global Acute Lymphocytic Leukemia Therapeutics Market, 2012-2020
Figure 54 : Global Acute Myeloid Leukemia Market, 2012-2020
Figure 55 : Chronic Lymphocytic Leukemia Market, 2012-2020
Figure 56 : Global Non-Hodgkin Lymphoma Drug Market, 2012-2020
Figure 57 : Global Hodgkin Lymphoma Treatment Market, 2012-2020
Figure 58 : Global Multiple Myeloma Treatment Market, 2012-2020
Figure 59 : Global Myelodysplastic Syndrome Market, 2012-2020
Figure 60 : Global Myeloproliferative Disorders Market, 2012-2020
Figure 61 : Global Myelofibrosis Market, 2012-2020
Figure 62 : Global Polycythemia Vera Market, 2012-2020
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Abbott Laboratories
- Abon Pharmaceuticals
- Ambit Biosciences
- Amgen
- Amphastar Pharmaceuticals
- Ariad Pharmaceuticals
- Astellas Pharma Us
- Astex Pharmaceuticals
- Astrazeneca
- Baxalta Inc.
- Baxter Healthcare Corp.
- Bayer Healthcare Pharmaceuticals
- Biogen Idec
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb
- Celgene Corp.
- Chugai Pharmaceutical
- C.R. Bard
- CZ Biomed Corp.
- Daiichi Sankyo Co. Ltd.
- Deciphera Pharmaceuticals
- Diagnocure
- Eisai Inc.
- ELI Lilly And Co.
- Enzon Pharmaceuticals
- Erytech Pharma Sa
- Exelixis
- GE Healthcare
- Genentech Inc.
- Genmab Inc.
- Gilead Sciences
- Glaxosmithkline
- Hologic
- Horiba Ltd.
- Johnson & Johnson
- The Medicines Co.
- Medkoo Biosciences
- Momenta Pharmaceuticals
- Noxxon Pharma Ag
- Portola Pharmaceuticals Inc.
- Opko Health
- Otsuka Pharmaceutical
- Pfizer
- Pharmacyclics
- Roche Diagnostics
- Sandoz International Gmbh
- Sanofi
- Siemens AG
- Spectrum Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Watson Pharmaceuticals Inc.
- YM Biosciences Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll